✦ LIBER ✦

Multicenter experience using telaprevir or boceprevir with peginterferon and ribavirin to treat hepatitis C genotype 1 after liver transplantation

✍ Scribed by Pungpapong, Surakit; Aqel, Bashar A.; Koning, Ludi; Murphy, Jennifer L.; Henry, Tanisha M.; Ryland, Kristen L.; Yataco, Maria L.; Satyanarayana, Raj; Rosser, Barry G.; Vargas, Hugo E.; Charlton, Michael R.; Keaveny, Andrew P.

Book ID: 121669549
Publisher: John Wiley and Sons
Year: 2013
Tongue: English
Weight: 418 KB
Volume: 19
Category: Article
ISSN: 1527-6465
DOI: 10.1002/lt.23669

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Ribavirin with either standard or pegyla

Ribavirin with either standard or pegylated interferon to treat recurrent hepatitis C after liver transplantation

✍ V. R. CICINNATI; S. IACOB; C. G. KLEIN; H. A. BABA; G. C. SOTIROPOULOS; P. HILGA 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 808 KB

Adherence to assigned dosing regimen and

Adherence to assigned dosing regimen and sustained virological response among chronic hepatitis C genotype 1 patients treated with boceprevir plus peginterferon alfa-2b/ribavirin

✍ Gordon, S. C.; Yoshida, E. M.; Lawitz, E. J.; Bacon, B. R.; Sulkowski, M. S.; Da 📂 Article 📅 2013 🏛 John Wiley and Sons 🌐 English ⚖ 296 KB

428 ADHERENCE TO ASSIGNED DOSING REGIMEN

428 ADHERENCE TO ASSIGNED DOSING REGIMEN AND SUSTAINED VIROLOGIC RESPONSE AMONG HEPATITIS C GENOTYPE 1 TREATMENT-NAIVE AND PEG/RIBAVIRIN TREATMENT-FAILURES TREATED WITH BOCEPREVIR PLUS PEGINTERFERON ALFA-2B/RIBAVIRIN

✍ S.C. Gordon; E.J. Lawitz; B.R. Bacon; M.S. Sulkowski; E.M. Yoshida; M. Davis; N. 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 178 KB

Adherence to Assigned Dosing Regimen and

Adherence to Assigned Dosing Regimen and Sustained Virologic Response Among Hepatitis C Genotype 1 Treatment-NaïVE and PEG/Ribavirin Treatment-Failures Treated With Boceprevir Plus Peginterferon Alfa-2B/Ribavirin

✍ Gordon, Stuart C. ;Lawitz, Eric J. ;Bacon, Bruce R. ;Sulkowski, Mark ;Yoshida, E 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 243 KB

A 48-week telaprevir-based triple combin

A 48-week telaprevir-based triple combination therapy improves sustained virological response rate in previous non-responders to peginterferon and ribavirin with genotype 1b chronic hepatitis C: A multicenter study

✍ Shimada, Noritomo; Tsubota, Akihito; Atsukawa, Masanori; Abe, Hiroshi; Ide, Tats 📂 Article 📅 2014 🏛 John Wiley and Sons 🌐 English ⚖ 600 KB

1044 TELAPREVIR IN HEPATITIS C GENOTYPE-

1044 TELAPREVIR IN HEPATITIS C GENOTYPE-1-INFECTED PATIENTS WITH PRIOR NON-RESPONSE, VIRAL BREAKTHROUGH OR RELAPSE TO PEGINTERFERON- ALFA-2A/B AND RIBAVIRIN THERAPY: SVR RESULTS OF THE PROVE3 STUDY

✍ Manns, M.; Muir, A.; Adda, N.; Jacobson, I.; Afdhal, N.; Heathcote, J.; Zeuzem, 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 91 KB